

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 13 returned.**☐ 1. Document ID: US 20030044893 A1

L2: Entry 1 of 13

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044893

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044893 A1

TITLE: Nectin polypeptides, polynucleotides, methods of making and use thereof

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baum, Peter R.	Seattle	WA	US	
<u>Fanslow, William C. III</u>	Normandy Park	WA	US	
Lofton, Timothy E.	Marysville	WA	US	
Sorensen, Eric A.	Lynnwood	WA	US	
Youakim, Adel	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/7.1, 514/12, 530/350, 530/388.1, 536/23.53

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RWC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	---------------------------	-----------------------

☐ 2. Document ID: US 20020168712 A1

L2: Entry 2 of 13

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168712

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020168712 A1

TITLE: Molecules designated LDCAM

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baum, Peter Robert	Seattle	WA	US	
<u>Fanslow, William Christian III</u>	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RWC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	---------------------------	-----------------------

☐ 3. Document ID: US 20020042368 A1

L2: Entry 3 of 13

File: PGPB

Apr 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020042368
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020042368 A1

TITLE: Integrin antagonists

PUBLICATION-DATE: April 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Fanslow, William C. III</u>	Seattle	WA	US	
Cerretti, Douglas P.	Seattle	WA	US	
Poindexter, Kurt M.	Seattle	WA	US	
Black, Roy A.	Seattle	WA	US	

US-CL-CURRENT: 514/12; 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RMIC	Draw Desc	Image
------	-----------	-------

☐ 4. Document ID: US 20020041864 A1

L2: Entry 4 of 13

File: PGPB

Apr 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020041864
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020041864 A1

TITLE: Method for treatment of tumors using photodynamic therapy

PUBLICATION-DATE: April 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Fanslow, William C. III</u>	Normandy Park	WA	US	
Thomas, Elaine K.	Seattle	WA	US	

US-CL-CURRENT: 424/85.1; 424/155.1, 604/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RMIC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 20020039992 A1

L2: Entry 5 of 13

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039992
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039992 A1

TITLE: Tek antagonists

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cerretti, Douglas P.	Seattle	WA	US	
Borges, Luis G.	Seattle	WA	US	
<u>Fanslow, William C. III</u>	Normandy Park	WA	US	

US-CL-CURRENT: 514/2; 424/130.1, 435/184, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KIMC	Draw Desc	Image
------	-----------	-------

☐ 6. Document ID: US 6410711 B1

L2: Entry 6 of 13

File: USPT

Jun 25, 2002

US-PAT-NO: 6410711

DOCUMENT-IDENTIFIER: US 6410711 B1

**** See image for Certificate of Correction ****TITLE: DNA encoding CD40 ligand, a cytokine that binds CD40

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
<u>Fanslow; William C.</u>	Normandy Park	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Greenbrae	CA		
Gibson; Marylou G.	Carlsbad	CA		
Morris; Arvia E.	Seattle	WA		
McGrew; Jeffrey T.	Seattle	WA		

US-CL-CURRENT: 536/23.5; 435/252.3, 435/320.1, 435/455, 435/69.1, 435/69.5, 530/350, 530/351, 536/23.1, 536/23.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KIMC	Draw Desc	Image
------	-----------	-------

☐ 7. Document ID: US 6391637 B1

L2: Entry 7 of 13

File: USPT

May 21, 2002

US-PAT-NO: 6391637

DOCUMENT-IDENTIFIER: US 6391637 B1

TITLE: Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA	98110	
<u>Fanslow; William C.</u>	Federal Way	WA	98023	
Spriggs; Melanie K.	Seattle	WA	98119	
Srinivasan; Subhashini	Kirkland	WA	98034	
Gibson; Marylou G.	Carlsbad	CA	92009	

US-CL-CURRENT: [435/377](#); [435/2](#), [435/326](#), [435/375](#), [435/383](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KIMC	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: US 6290972 B1

L2: Entry 8 of 13

File: USPT

Sep 18, 2001

US-PAT-NO: 6290972

DOCUMENT-IDENTIFIER: US 6290972 B1

TITLE: Method of augmenting a vaccine response by administering CD40 ligand

DATE-ISSUED: September 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
<u>Fanslow; William C.</u>	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		

US-CL-CURRENT: [424/278.1](#); [435/440](#), [435/69.1](#), [514/2](#), [514/8](#), [514/885](#), [530/350](#),
[536/23.1](#), [536/23.4](#), [536/23.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KIMC	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: US 6264951 B1

L2: Entry 9 of 13

File: USPT

Jul 24, 2001

US-PAT-NO: 6264951

DOCUMENT-IDENTIFIER: US 6264951 B1

TITLE: Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L

DATE-ISSUED: July 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
<u>Fanslow; William C.</u>	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		

US-CL-CURRENT: [424/184.1](#); [424/185.1](#), [424/85.1](#), [514/12](#), [514/2](#), [514/8](#), [514/885](#),
[530/350](#), [530/351](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KIMC	Draw Desc	Image
------	-----------	-------

☐ 10. Document ID: US 6087329 A

L2: Entry 10 of 13

File: USPT

Jul 11, 2000

US-PAT-NO: 6087329

DOCUMENT-IDENTIFIER: US 6087329 A

TITLE: CD40 ligand polypeptide

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
<u>Fanslow; William C.</u>	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		

US-CL-CURRENT: 514/8; 514/2, 514/885, 530/350, 530/351

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

[Generate Collection](#)[Print](#)

Term	Documents
CD40L.USPT,PGPB.	755
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	1969
CD40S	0
LIGAND.USPT,PGPB.	54478
LIGANDS.USPT,PGPB.	44605
(1 AND (CD40L OR (CD40 ADJ LIGAND))).USPT,PGPB.	13
(L1 AND (CD40L OR CD40 ADJ LIGAND)).USPT,PGPB.	13

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 13 of 13 returned.**☐ 11. Document ID: US 5981724 A

L2: Entry 11 of 13

File: USPT

Nov 9, 1999

US-PAT-NO: 5981724

DOCUMENT-IDENTIFIER: US 5981724 A

TITLE: DNA encoding CD40 ligand, a cytokine that binds CD40

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
<u>Fanslow; William C.</u>	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		
Morris; Arvia E.	Seattle	WA		
McGrew; Jeffrey T.	Seattle	WA		

US-CL-CURRENT: 536/23.5; 435/252.3, 435/320.1, 435/455, 435/471, 435/69.1, 435/69.7, 536/23.1[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#)☐ 12. Document ID: US 5962406 A

L2: Entry 12 of 13

File: USPT

Oct 5, 1999

US-PAT-NO: 5962406

DOCUMENT-IDENTIFIER: US 5962406 A

**** See image for Certificate of Correction ****TITLE: Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
<u>Fanslow; William C.</u>	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		
Morris; Arvia E.	Seattle	WA		
McGrew; Jeffrey T.	Seattle	WA		

US-CL-CURRENT: [514/8](#); [514/12](#), [514/2](#), [514/885](#), [530/350](#), [536/23.1](#), [536/23.4](#), [536/23.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 13. Document ID: US 5961974 A

L2: Entry 13 of 13

File: USPT

Oct 5, 1999

US-PAT-NO: 5961974

DOCUMENT-IDENTIFIER: US 5961974 A

TITLE: Monoclonal antibodies to [CD40 ligand](#), pharmaceutical composition comprising the same and hybridomas producing the same

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		

US-CL-CURRENT: [424/154.1](#); [424/130.1](#), [424/141.1](#), [424/143.1](#), [424/144.1](#), [424/153.1](#), [424/173.1](#), [435/326](#), [435/332](#), [435/334](#), [435/343](#), [435/343.1](#), [435/343.2](#), [435/346](#), [435/452](#), [435/70.21](#), [530/387.1](#), [530/387.9](#), [530/388.1](#), [530/388.22](#), [530/388.7](#), [530/388.73](#), [530/388.75](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

[Generate Collection](#)[Print](#)

Term	Documents
CD40L.USPT,PGPB.	755
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	1969
CD40S	0
LIGAND.USPT,PGPB.	54478
LIGANDS.USPT,PGPB.	44605
(1 AND (CD40L OR (CD40 ADJ LIGAND))).USPT,PGPB.	13
(L1 AND (CD40L OR CD40 ADJ LIGAND)).USPT,PGPB.	13

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD30L.USPT.	55
CD30LS	0
(CD30L AND 6).USPT.	15
(L6 AND CD30L).USPT.	15

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L8

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** **Friday, May 02, 2003** [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

*DB=USPT; PLUR=YES; OP=ADJ*L8 L6 and cd30L15 L8*DB=USPT,PGPB; PLUR=YES; OP=ADJ*L7 L6 and cd30L39 L7L6 L5 same (treat\$ or therap\$ or prevent\$ or block\$ or suppress\$ or inhibit\$)248 L6L5 (cd40L or cd40 adj ligand or gp39) same (cancer\$ or tumor\$ or tumour\$)543 L5L4 L3 and photodynamic1 L4L3 L2 and (cancer\$ or tumor\$ or tumour\$)13 L3L2 L1 and (cd40L or cd40 adj ligand)13 L2L1 fanslow-william\$22 L1

END OF SEARCH HISTORY

WEST**End of Result Set**

Generate Collection

Print

L9: Entry 6 of 6

File: USPT

Jun 29, 1999

DOCUMENT-IDENTIFIER: US 5916910 A

TITLE: Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

Brief Summary Text (86):

antiarthritic agents, such as anti-CD4 monoclonal antibodies, phospholipase A1 inhibitor, loteprednol, tobramycin, combinations of loteprednol and tobramycin, salnacedin, amiprilose, anakinra, anergix, anti-B7 antibody, anti-CD3H, anti-gp39, anti-MHC MABs, antirheumatic peptides, anti-Tac(Fv)-PE40, AP-1 inhibitors, AR-324, purine nucleotide phosphorylase inhibitors (e.g., BCX-5), bindarit, CD2 antagonist (e.g., BTI-322), campath-1H, CD4 antagonist (e.g., CE9.1 and SB-210396), tumor necrosis factor antagonist (e.g., p80 TNFR, rhTNFbp, peptide T, CentTNF, thalidomide, CDP-571 and TBP-1), cobra venom factor, interleukin 1a agonist (e.g., cytogenin), interleukin 2 receptor antagonist (e.g., dactiliximab), ICAM 1 antagonist (e.g., enlimomab), interleukin 1 beta converting enzyme inhibitors (e.g., ICE-inhibitors), interferons (e.g., thymocartin), interleukin-10, interleukin-13, interleukin 1 antagonist (e.g., SR-31747 and TJ-114), interleukin-2 antagonist (e.g., sirolimus), phospholipase C inhibitor, neurokinin 1 antagonist (e.g., L-733060), laflunimus, leflunomide, leucotriene antagonists, levamisole, LFA3TIP, macrocyclic lactone, MHC class II inhibitors, mizoribine, mycophenolate mofetil, Nfkb inhibitors, oncolysin CD6, peldesine, pidotimod, PKC-RACK inhibitors, PNP inhibitors, reumacon, CD28 antagonist, roquinimex, RWJ-50271, subreum, T7 vector, tacrolimus, VLA antagonist (e.g., TBC-772), transforming growth factor beta agonist, methionine synthase inhibitors (e.g., vitamin B12 antagonist), adenosine A2 receptor agonist (e.g., YT-146), CD5 antagonist (e.g., zolimomab), 5-lipoxygenase inhibitor (e.g., zileuton, tenidap, and ABT-761), cyclooxygenase inhibitor (e.g., tenoxicam, talmetacin, piroxicam, piroxicam cinnamate, oxaprozin, NXTHIO, ML-3000, mofezolac, nabumetone, flurbiprofen, aceclofenac, diclofenac, and dexibuprofen), metalloproteinase inhibitor (e.g., XR-168, TNF convertase inhibitors, GI-155704A, AG-3340 and BB-2983), nitric oxide synthase inhibitors (i.e., ARL-16556), phospholipase A2 inhibitor (e.g., ARL-67974), selectin antagonist (e.g., CAM inhibitors), leucotriene B4 antagonist (e.g., CGS-25019C), collagenase inhibitor (e.g., GR-129574A), cyclooxygenase 2 inhibitor (e.g., meloxicam), thromboxane synthase inhibitor (e.g., curcumin), cysteine protease inhibitor (e.g., GR-373), metalloproteinase inhibitor (D-5410), lipocortins synthesis agonist (e.g., rimexolone, predonisolone 21-farnesylate, HYC-141, and deflazacort), chelating agent (diacerein), elastase inhibitors, DNA directed RNA polymerase inhibitor (e.g., estrogens), oxygen radical formation antagonist (e.g., glucosamine sulfate), thrombin inhibitors (e.g., GS-522), collagen inhibitors (e.g., halofuginone), hyaluronic acid agonist (e.g., NRD-101, hylan, Dispasan, and Hyalart), nitric oxide antagonists (e.g., hydroxocobalamin), stromelysin inhibitors (e.g., L-758354), prostaglandin E1 agonist (e.g., misoprostol, and misoprostol+diclofenac), dihydrofolate reductase inhibitor (e.g., trimetrexate, and MX-68), opioid antagonist (e.g., nalmefene), corticotropin releasing factor antagonist (e.g., NBI-103, and NBI-104), proteolytic enzyme inhibitor (e.g., protease nexin-1, and NCY-2010), bradykinin antagonist (e.g., tachykinin antagonists, and NPC-17731), growth hormone antagonist (e.g., octreotide), phosphodiesterase IV inhibitor (e.g., PDEIV inhibitors), gelatinase inhibitor (e.g., REGA-3G12), free radical scavengers (e.g., SIDR-1026), prostaglandin synthase inhibitors (e.g., sulfasalazine), phenylbutazone, penicillamine, salsalate, azathioprine, indomethacin, meclofenamate sodium, gold sodium thiomalate, ketoprofen, auranofin, aurothioglucose, tolmetin sodium, and the

like;

Brief Summary Text (111):

multiple sclerosis agents, such as 4-aminopyridine, 15-+-deoxyspergualin, ACTH, amantadine, antibody adjuvants (e.g., poly-ICLC, and poly-IC+poly-L-lysine+carboxymethylcellulose), anti-cytokine MAb (CDP-835), anti-inflammatory (e.g., CY-1787, and CY-1503), anti-selectin MAb (e.g., CY-1787), anti-TCR MAb (e.g., NBI-114, NBI-115, and NBI-116), baclofen, bethanechol chloride, carbamazepine, carbohydrate drugs (e.g., CY-1503), clonazepam, CNS and immune system function modulators (e.g., NBI-106, and NBI-107), cyclophosphamide, cyclosporine A, cytokines (e.g., IFN-.alpha., alfaferone, IFN-.beta. 1b, betaseron, TGF-.beta.2, PEG-TGF-.beta.2, betakine, IFN-.beta./Rebif, frone, interferon-.beta., and IFN-.beta.), CD4+T cell inhibitors (e.g., AnergiX), CD28 antagonists (e.g., B7-1, B7-2, and CD28), directcytotoxicity therapies (e.g., benzoporphyrin derivative (BPD)), FK-506, growth factors (e.g., glial growth factor, GGF, nerve growth factors, TGF-.beta.2, PEG-TGF-.beta.2, and betakine), humanized MAb (e.g., anti-IFN-.gamma.MAb, smart anti-IFN-.gamma.MAB, anti-Tac antibody, and smart anti-Tac antibody), humanized anti-CD4 MAB (e.g., anti-CD4 MAB, centara), hydrolase stimulants (e.g., castanospermine), IFN-.alpha., IFN-.gamma. antagonist (e.g., anti-IFN-.gamma. MAB, and smart anti-IFN-.gamma. MAB), IL-2 antagonists (e.g., tacrolimus, FK-506, FR-900506, Fujimycin, Prograf, IL-2 fusion toxin, and DAB.sub.389 IL-2), IL-4 antagonists (e.g., IL-4 fusion toxin, and DAB.sub.389 IL-4), immune-mediated neuronal damage inhibitors (e.g., NBI-114, NBI-115, and NBI-116), immunoglobins, immunostimulants (e.g., poly-ICLC, edelfosine, ALP, ET-18-OCH3, ET-18-OME, NSC-24, and poly-IC+poly-L-lysine+carboxymethylcellulose), immunosuppressants (e.g., azathioprine, AI-100 animal protein, rDNA human protein AI-101, peptide, AI-102, castanospermine, tacrolimus, FK-506, FR-900506, Fujimycin, Prograf, anti-leukointegrin MAB, Hu23F2G, primatized anti-CD4 antibody, CE9.1, Galaptin 14-1, GL14-1, Lectin-1, recombinant IML-1, linomide, roquinimex, LS-2616, transcyclo-pentanyl purine analogs, MS-6044, spanidin, 15-deoxyspergualin, deoxyspergualine, gusperimus HCL, NSC-356894, NKT-01, TCR, CD3/Ti, cyclosporine, OL-27-400, SandImmune, Human IL-10, monogens, anti-TCR MABs, TCAR MABs, Monogen TM19, Monogen TM27, Monogen TM29, Monogen TM31, peptigen TP12, anti-CD4 MAB, cantara, immunophilins, VX-10367, VX-10393, VX-10428, synthetic basic copolymer of amino acids, copolymer-1, COP-1, T lymphocyte immunofusion (TIF) protein, and cyclophosphamide), integrin antagonists (e.g., anti-integrin (cell adhesion molecule .alpha.4.beta.1 integrin) MABs, AN-100225, and AN-100226), interferon agonists (e.g., poly-ICLC, and poly-IC+poly-L-lysine+carboxymethylcellulose), interferon-.beta.-1b, isoprinosine, IV methylprednisolone, macrolides (e.g., tacrolimus, FK-506, FR-900506, Fujimycin, and Prograf), MAO B inhibitors (e.g., selegiline, and Parkinyl), methotrexate, mitoxantrone, muscle relaxants (e.g., RGH-5002), muscarinic antagonists (e.g., RGH-5002), neurosteroids (e.g., NBI-106, and NBI-107), octapeptides (e.g., peptide T), oxybutinin chloride, oxygen free radical antagonists (e.g., tetrandrine, biobenzylisoquinoline alkaloid), peptide agonists (e.g., peptide T), phenoxybenzamine, phospholipase C inhibitors (e.g., edelfosine, ALP, ET-18-OCH3, ET-18-OME, NSC-24), photodynamic therapies (e.g., benzoporphyrin derivative (BPD)), plasmapheresis, platelet activating factor antagonists (e.g., ginkgolide B, and BN-52021), potassium channel antagonists (e.g., aminodiaquine, and EL-970), propranolol, prostaglandin synthase inhibitors (e.g., sulfasalazine, salazosulfa-pyridine, PJ-306, SI-88, azulfidine, salazopyrin), protease antagonists (e.g., ginkgolide B, and BN-52021), recombinant soluble IL-1 receptors, spergualin analogs (e.g., spanidin, 15-deoxyspergualin, deoxyspergualine, gusperimus HCL, NSC-356894, NKT-01), TCR peptide decoys (e.g., NBI-114, NBI-115, and NBI-116), TCR peptidomimetic decoys (e.g., NBI-114, NBI-115, and NBI-116), TCR peptide vaccines (e.g., AI-208 (V.beta.6.2/6.5 phenotype)), selectin antagonists (e.g., lectin-1, and recombinant IML-1), soluble TNF receptor I, TCARs (e.g., TCR, CD3/Ti, and peptigen TP12), TNF antagonists (e.g., thalidomide, and TNF inhibitors), tricyclic antidepressants, and the like;

Brief Summary Text (116):

psoriasis agents, such as 5-LO inhibitors (e.g., Wy-50295, Wy-49232, Lonapalene, RS-43179, MK-886, L-663536, ETH-615, DUP-654, Zileuton, epocarbazolin-A, and A-64077), 5-LO/CO inhibitors (e.g., BF-397, Tenidap, CP-309, and CP-66248), angiogenesis inhibitors (e.g., platelet factor 4), anticancer antibiotic (e.g., AGM-1470, and TNP-470), anti-inflammatory cytochrome P450 oxidoreductase inhibitors

(e.g., DuP-630, and DuP-983), antiproliferative compounds (e.g., Zyn-Linker), arachidonic acid analogues (e.g., CD581, and CD554), arachidonic acid antagonists (e.g., Lonopalene, RS-43179, triamcinolone acetonide with penetration enhancer Azone, betamethasone dipropionate steroid wipe, G-202, Halobetasol propionate, ultravate, Halometasone, C-48401-Ba, and Sicorten), beta-glucan receptor antagonists, betamethasone steroid wipes, calcium metabolic moderators (e.g., Tacalcitol, Bonealfa, TV-02 ointment, Ro-23-6474, KH-1060, Calcipotriol, BMS-181161, BMY-30434, Dovonex, and Divonex), CD4 binding inhibitors (e.g., PIC 060), cell adhesion compounds (e.g., CY-726, VCAM-1, ELAM-1, and ICAM), cell adhesion inhibitors (e.g., selectin inhibitor, GM-1930), cellular aging inhibitors (e.g., Factor X), corticosteroids (e.g., Halobetasol propionate, ultravate, Halometasone, C-48401-Ba, and Sicorten), cyclosporin analogues (e.g., IMM-125), dihydrofolate reductase inhibitors (e.g., G-301, dichlorobenzoprim, methotrexate, and methotrexate in microsphere delivery system), E-selectin inhibitors (e.g., ISIS 4730), endogenous active form of vitamin D.sub.3 (e.g., Calcitriol, and Du-026325), fibroblast growth factor antagonists (e.g., Saporin mitotoxin, and Steno-Stat), fumagillin analogues (e.g., AGM-1470, and TNP-470), G-proteins and signal transduction compounds (e.g., CPC-A), gel formulations for acne (e.g., nicotinamide, N-547, and Papulex), growth hormone antagonists (e.g., Octreotide, Sandostatin, Lanreotide, angiopeptin, BIM-23014, and Somatuline), humanized antibodies (e.g., anti-CD4 antibody), hydroorotate dehydrogenase inhibitors (e.g., Brequinar sodium, bipenquinat, and DuP-785), ICAM-1 inhibitors (e.g., ISIS 939), IL-1 and other cytokine inhibitors (e.g., Septanil), IL-1 converting enzyme inhibitors, IL-1 receptor antagonists (e.g., Antril), IL-2 antagonists (e.g., Tacrolimus, Prograf, and FK-506), IL-2 receptor-targeted fusion toxins (DAB389IL-2), IL-8 receptors, immunostimulants (e.g., Thymopentin, and Timunox), immunosuppressants (e.g., XomaZyme-CD5 Plus, cyclosporine, Sandimmune, SR-31747, anti-CD11, 18 MAb, Tacrolimus, Prograf, FK-506, and FK-507), immunosuppressive agents targeting FK506 (e.g., immunophilins, VX-10367, and VX-10428), immunotoxins MAb directed against CD antigen (e.g., XomaZyme-CD5 Plus), leukotriene antagonists (e.g., Sch-40120, Wy-50295, and Wy-49232), leukotriene B4 antagonists (e.g., SC-41930, SC-50605, SC-48928, ONO-4057, LB-457, LY-255283, LY-177455, LY-223982, LY-223980, and LY-255253), leukotriene synthesis inhibitors (MK-886, and L-663536), lipase clearing factor inhibitors (e.g., 1-docosanol, and lidakol), lipid encapsulated reducing agent (e.g., Dithranol), liposomal gel (e.g., Dithranol), LO inhibitors (e.g., CD581, CD554, Masoprocol, and Actinex), lithium succinate ointments (e.g., lithium salts, and Efalith), LO/CO inhibitors (e.g., P-8892, P-8977, CHX-108, and FPL-62064), membrane integrity agonists (e.g., lithium salts, and Efalith), microtubule inhibitors (e.g., Posophyllotoxin-containing compound, and Psorex), octapeptide somatostatin analogues (e.g., Lanreotide, angiopeptin, BIM-23014, and Somatuline), oligonucleotides (e.g., ISIS 4730, ISIS 3801, ISIS 1939, and IL-1 inhibitors), peptide agonists (e.g., octapeptide, and peptide T), PKC inhibitors, phospholipase A2 compounds, phospholipase D compounds, photodynamic anticancer agents (e.g., 5-aminolevulinic acid, and 5-ALA), photodynamic therapies (e.g., benzoporphyrin derivative, synthetic chlorins, synthetic porphyrins, and EF-9), photosensitizer (e.g., Porfimer sodium), PKC inhibitors (e.g., Safingol, and Kynac), platelet activating factor antagonists (e.g., TCV-309), platelet aggregation inhibitors (e.g., CPC-A), prodrug NSAIDs (e.g., G-201), prostaglandin agonist (e.g., eicosapentaenoic acid+gamma-linolenic acid combination, and Efamol Marine), protein inhibitors (e.g., SPC-103600, and SPC-101210), protein kinase C (PKC) inhibitors (e.g., Ro-31-7549, Ro-31-8161, and Ro-31-8220), protein synthesis antagonists (e.g., Calcitriol, Du-026325, LG-1069, LG-1064, AGN-190168, Namiroten, and CBS-211A), purine nucleoside phosphorylase inhibitors (e.g., BCX-34), radical formation agonists (e.g., benzoporphyrin derivative), recombinant antileukoproteins (e.g., ALP-242), retinoids (e.g., BMY-30123, LG-1069, and LG-1064), retinoid derivatives (e.g., AGN-190168), rapamycin binding proteins (FKBP) (e.g., immunophilins, VX-10367, and VX-10428), second generation monoaromatic retinoids (e.g., Acitretin, and Neotigason), soluble IL-1, IL-4 and IL-7 receptors, somatostatin and somatostatin analogues (e.g., Octreotide, and Sandostatin), steroids, (e.g., AGN-191743), streptomyces anulatus isolates (e.g., epocarbazolin-A), superoxide dismutase (e.g., EC-SOD-B), thymidylate synthase inhibitors (e.g., AG-85, MPI-5002, 5-FU in biodegradable gel-like matrix, 5-FU and epinephrine in biodegradable gel-like matrix, and AccuSite), topical formulations (e.g., P-0751, and P-0802), transglutaminase inhibitors, tyrphostin EGF receptor kinase blockers (e.g., AG-18, and AG-555), VCAM-1 inhibitors (e.g., ISIS 3801), vitamin D analogues (e.g., Ro-23-6474, KH-1060, Calcipotriol, BMS-181161, BMY-30434,

Dovonex, and Divonex), vitamin D.sub.3 analogues (e.g., Tacalcitol, Bonealfa, TV-02 ointment), and vitamin D.sub.3 derivatives (e.g., 1,2-diOH-vitamin D.sub.3), and the like;

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD40L.USPT.	248
CD40LS.USPT.	2
CD40.USPT.	889
CD40S	0
LIGAND.USPT.	40761
LIGANDS.USPT.	33419
GP39.USPT.	121
GP39S	0
CD30L.USPT.	55
CD30LS	0
PHOTODYNAMICS\$	0
((CD40L OR CD40 ADJ LIGAND OR GP39 OR CD30L) AND PHOTODYNAMICS\$.USPT.	6

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L9

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: **Friday, May 02, 2003** [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT; PLUR=YES; OP=ADJ

L9 (cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic\$

6 L9

L8 L6 and cd30L

15 L8

DB=USPT,PGPB; PLUR=YES; OP=ADJ

L7 L6 and cd30L

39 L7

L6 L5 same (treat\$ or therap\$ or prevent\$ or block\$ or suppress\$ or inhibit\$)

248 L6

L5 (cd40L or cd40 adj ligand or gp39) same (cancer\$ or tumor\$ or tumour\$)

543 L5

L4 L3 and photodynamic

1 L4

L3 L2 and (cancer\$ or tumor\$ or tumour\$)

13 L3

L2 L1 and (cd40L or cd40 adj ligand)

13 L2

L1 fanslow-william\$

22 L1

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD30L.DWPI,EPAB,JPAB,USPT,PGPB.	278
CD30LS	0
TUMORS	0
TUMOR.DWPI,EPAB,JPAB,USPT,PGPB.	36175
TUMORA.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORACTIVITY.DWPI,EPAB,JPAB,USPT,PGPB.	9
TUMORADENOCA.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORAGENT.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORAL.DWPI,EPAB,JPAB,USPT,PGPB.	661
TUMORALE.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORALLY.DWPI,EPAB,JPAB,USPT,PGPB.	45
((CD30L)SAME(TUMORS\$ OR TUMOURS\$ OR CANCERS\$)SAME (TREAT\$ OR INHIBIT\$ OR BLOCK\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$)).USPT,PGPB,JPAB,EPAB,DWPI.	11

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L12

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Friday, May 02, 2003 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L12</u>	(cd30L)same(tumor\$ or tumour\$ or cancer\$)same (treat\$ or inhibit\$ or block\$ or suppress\$ or prevent\$ or therap\$)	11	<u>L12</u>
<i>DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L11</u>	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic\$	1	<u>L11</u>
<u>L10</u>	L9	0	<u>L10</u>
<i>DB=USPT; PLUR=YES; OP=ADJ</i>			
<u>L9</u>	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic\$	6	<u>L9</u>
<u>L8</u>	L6 and cd30L	15	<u>L8</u>
<i>DB=USPT,PGPB; PLUR=YES; OP=ADJ</i>			
<u>L7</u>	L6 and cd30L	39	<u>L7</u>
<u>L6</u>	L5 same (treat\$ or therap\$ or prevent\$ or block\$ or suppress\$ or inhibit\$)	248	<u>L6</u>
<u>L5</u>	(cd40L or cd40 adj ligand or gp39) same (cancer\$ or tumor\$ or tumour\$)	543	<u>L5</u>
<u>L4</u>	L3 and photodynamic	1	<u>L4</u>
<u>L3</u>	L2 and (cancer\$ or tumor\$ or tumour\$)	13	<u>L3</u>
<u>L2</u>	L1 and (cd40L or cd40 adj ligand)	13	<u>L2</u>
<u>L1</u>	fanslow-william\$	22	<u>L1</u>

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD30L.DWPI,EPAB,JPAB,USPT,PGPB.	278
CD30LS	0
TUMORS\$	0
TUMOR.DWPI,EPAB,JPAB,USPT,PGPB.	36175
TUMORA.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORACTIVITY.DWPI,EPAB,JPAB,USPT,PGPB.	9
TUMORADENOCA.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORAGENT.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORAL.DWPI,EPAB,JPAB,USPT,PGPB.	661
TUMORALE.DWPI,EPAB,JPAB,USPT,PGPB.	1
TUMORALLY.DWPI,EPAB,JPAB,USPT,PGPB.	45
((CD30L)SAME(TUMORS\$ OR TUMOUR\$ OR CANCERS\$)SAME (TREAT\$ OR INHIBIT\$ OR BLOCK\$ OR SUPPRESS\$ OR PREVENT\$ OR THERAP\$)).USPT,PGPB,JPAB,EPAB,DWPI.	11

[There are more results than shown above. Click here to view the entire set.](#)

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index

Database: IBM Technical Disclosure Bulletins

Search:

L12

[Refine Search](#)

[Recall Text](#)

[Clear](#)

Search History

DATE: Friday, May 02, 2003 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L12</u>	(cd30L)same(tumor\$ or tumour\$ or cancer\$)same (treat\$ or inhibit\$ or block\$ or suppress\$ or prevent\$ or therap\$)	11	<u>L12</u>
<i>DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L11</u>	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic\$	1	<u>L11</u>
<u>L10</u>	L9	0	<u>L10</u>
<i>DB=USPT; PLUR=YES; OP=ADJ</i>			
<u>L9</u>	(cd40L or cd40 adj ligand or gp39 or cd30L) and photodynamic\$	6	<u>L9</u>
<u>L8</u>	L6 and cd30L	15	<u>L8</u>
<i>DB=USPT,PGPB; PLUR=YES; OP=ADJ</i>			
<u>L7</u>	L6 and cd30L	39	<u>L7</u>
<u>L6</u>	L5 same (treat\$ or therap\$ or prevent\$ or block\$ or suppress\$ or inhibit\$)	248	<u>L6</u>
<u>L5</u>	(cd40L or cd40 adj ligand or gp39) same (cancer\$ or tumor\$ or tumour\$)	543	<u>L5</u>
<u>L4</u>	L3 and photodynamic	1	<u>L4</u>
<u>L3</u>	L2 and (cancer\$ or tumor\$ or tumour\$)	13	<u>L3</u>
<u>L2</u>	L1 and (cd40L or cd40 adj ligand)	13	<u>L2</u>
<u>L1</u>	fanslow-william\$	22	<u>L1</u>

END OF SEARCH HISTORY